Patient-important benefits of clearing the hepatitis C virus through treatment: A simulation model

Journal of Hepatology

Volumn 60, Issue 6, 2014, Pages 1118-1126

  Innes, Hamish ^a,b   Goldberg, David ^a,b   Dusheiko, Geoffrey ^c   Hayes, Peter ^d   Mills, Peter R ^e   Dillon, John F ^f   Aspinall, Esther ^a,b   Barclay, Stephen T ^g   Hutchinson, Sharon J ^a,b  

^a GLASGOW CALEDONIAN UNIVERSITY   (United Kingdom)

^b HEALTH PROTECTION SCOTLAND   (United Kingdom)

^c ROYAL FREE HOSPITAL   (United Kingdom)

^d ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^e GARTNAVEL GENERAL HOSPITAL   (United Kingdom)

^f UNIVERSITY OF DUNDEE   (United Kingdom)

^g GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

Adverse effects; Antiviral treatment; Chronic hepatitis C; Hepatitis C; Markov model; Patient centred; Patient important outcomes; Risk benefit ratio; Simulation model

Indexed keywords

ADULT; ADVERSE OUTCOME; ARTICLE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FAILURE; LIVER FIBROSIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SIMULATION; SUSTAINED VIRAL RESPONSE; TREATMENT RESPONSE; VIRAL CLEARANCE; ANTIVIRAL THERAPY; DEATH; DECOMPENSATED LIVER CIRRHOSIS; DISEASE COURSE; DRUG EFFICACY; DRUG TOLERABILITY; HIT MODEL; LIFESPAN; MODEL; PROBABILITY; TREATMENT OUTCOME; DECISION SUPPORT SYSTEM; DRUG COMBINATION; DRUG EFFECTS; HEPACIVIRUS; HEPATITIS C, CHRONIC; MIDDLE AGED; MORTALITY; PROCEDURES; PROGNOSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL; VIROLOGY;

ALPHA INTERFERON; ANTIVIRUS AGENT; RIBAVIRIN;

ADULT; ANTIVIRAL AGENTS; DECISION SUPPORT TECHNIQUES; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LIVER CIRRHOSIS; MARKOV CHAINS; MIDDLE AGED; MODELS, STATISTICAL; PROGNOSIS; RIBAVIRIN; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX;

EID: 84901237436     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2014.01.020     Document Type: Article

References (66)

1. P. Marcellin, T. Asselah, and N. Boyer Fibrosis and disease progression in hepatitis C Hepatology 36 2002 S47 S56
2. G. D'Amico, G. Garcia-Tsao, and L. Pagliaro Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies J Hepatol 44 2006 217 231
3. B.R. Edlin Perspective: test and treat this silent killer Nature 474 2011 S18 S19
4. Detonating a viral time bomb-the hepatitis C pandemic Lancet 381 2013 178
5. EASL Clinical Practice Guidelines Management of hepatitis C virus infection J Hepatol 55 2011 245 264
6. M.M. Manos, C.K. Ho, R.C. Murphy, and V.A. Shvachko Physical, social, and psychological consequences of treatment for hepatitis C: a community-based evaluation of patient-reported outcomes Patient 6 2013 23 34
7. M.W. Fried Side effects of hepatitis c and their management Hepatology 36 2002 S237 S244
8. US Food and Drug Administration. Drug safety communication. http://www.fda.gov/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ucm332860.htm. Accessed January 2013.
9. C. Hezode, H. Fontaine, C. Dorival, D. Larrey, F. Zoulim, and V. Canva et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the french early access programme (anrs c020-cupic)-nct01514890 J Hepatol 59 2013 434 441
10. B. Maasoumy, K. Port, A.A. Markova, B.C. Serrano, M. Rogalska-Taranta, and L. Sollik et al. Eligibility and safety of triple therapy for hepatitis C: lessons learned from the first experience in a real world setting PLoS One 8 2013 e55285
11. D.L. Wyles Antiviral resistance and the future landscape of hepatitis C virus infection therapy J Infect Dis 207 2013 S33 S39
12. H.J. Alter, and L.B. Seeff Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome Semin Liver Dis 20 2000 17 35
13. L.B. Seeff Natural history of chronic hepatitis C Hepatology 36 2002 S35 S46
14. F. Poordad, J. McCone Jr., B.R. Bacon, S. Bruno, M. Manns, and M.S. Sulkowski et al. Boceprevir for untreated chronic HCV genotype 1 infection N Engl J Med 364 2011 1195 1206
15. I.M. Jacobson, J.G. McHutchison, G. Dusheiko, A.M. Di Bisceglie, K.R. Reddy, and N.H. Bzowej et al. Telaprevir for previously untreated chronic hepatitis C virus infection N Engl J Med 364 2011 2405 2416
16. H.A. Innes, S.J. Hutchinson, S. Allen, D. Bhattacharyya, P. Bramley, and T.E. Delahooke et al. Ranking predictors of a sustained viral response for patients with chronic hepatitis C treated with pegylated interferon and ribavirin in Scotland Eur J Gastroenterol Hepatol 24 2012 646 655
17. N. Brau Evaluation of the hepatitis C virus-infected patient: the initial encounter Clin Infect Dis 56 2013 853 860
18. P. Trembling, S. Tanwar, W. Rosenberg, and G. Dusheiko Treatment decisions and contemporary vs. pending treatments for hepatitis C Nat Rev Gastroenterol Hepatol 10 2013 713 728
19. G.J. Dore The changing therapeutic landscape for hepatitis C Med J Aust 196 2012 629 632
20. E.M. Wever, J. Hugosson, E.A. Heijnsdijk, C.H. Bangma, G. Draisma, and H.J. de Koning To be screened or not to be screened? Modeling the consequences of PSA screening for the individual Br J Cancer 107 2012 778 784
21. B. Sharif, J. Kopec, H. Wong, P. Fines, E. Sayre, and R. Liu et al. Uncertainty analysis in population-based disease microsimulation models Epidemiol Res Int 2012 2012 14 10.1155/2012/610405
22. N.K. Martin, P. Vickerman, A. Miners, G.R. Foster, S.J. Hutchinson, and D.J. Goldberg et al. Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations Hepatology 55 2012 49 57
23. D.B. Rein, B.D. Smith, J.S. Wittenborn, S.B. Lesesne, L.D. Wagner, and D.W. Roblin et al. The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings Ann Intern Med 156 2012 263 270
24. R. Grieve, J. Roberts, M. Wright, M. Sweeting, D. DeAngelis, and W. Rosenberg et al. Cost effectiveness of interferon alpha or peginterferon alpha with ribavirin for histologically mild chronic hepatitis C Gut 55 2006 1332 1338
25. M. Wright, R. Grieve, J. Roberts, J. Main, and H.C. Thomas Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation Health Technol Assess 10 2006 1 113
26. G.L. Davis, M.J. Alter, H. El-Serag, T. Poynard, and L.W. Jennings Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression Gastroenterology 138 2010 513 521
27. S.J. Hutchinson, S.M. Bird, and D.J. Goldberg Modeling the current and future disease burden of hepatitis C among injection drug users in Scotland Hepatology 42 2005 711 723
28. D.B. Rein, J.S. Wittenborn, C.M. Weinbaum, M. Sabin, B.D. Smith, and S.B. Lesesne Forecasting the morbidity and mortality associated with prevalent cases of pre-cirrhotic chronic hepatitis C in the United States Dig Liver Dis 43 2011 66 72
29. S. Deuffic-Burban, P. Deltenre, A. Louvet, V. Canva, S. Dharancy, and A. Hollebecque et al. Impact of viral eradication on mortality related to hepatitis C: a modeling approach in France J Hepatol 49 2008 175 183
30. S. Deuffic-Burban, P. Deltenre, M. Buti, T. Stroffolini, J. Parkes, and N. Muhlberger et al. Predicted effects of treatment for HCV infection vary among European countries Gastroenterology 143 2012 974 985
31. S. Deuffic-Burban, G. Babany, I. Lonjon-Domanec, P. Deltenre, V. Canva-Delcambre, and S. Dharancy et al. Impact of pegylated interferon and ribavirin on morbidity and mortality in patients with chronic hepatitis C and normal aminotransferases in France Hepatology 50 2009 1351 1359
32. K. Ishak, A. Baptista, L. Bianchi, F. Callea, J. De Groote, and F. Gudat et al. Histological grading and staging of chronic hepatits J Hepatol 22 1995 696 699
33. G. Fattovich, G. Giustina, F. Degos, F. Tremolada, G. Diodati, and P. Almasio et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients Gastroenterology 112 1997 463 472
34. R. Chou, D. Hartung, B. Rahman, N. Wasson, E.B. Cottrell, and R. Fu Comparative effectiveness of antiviral treatment for hepatitis C virus infection in adults: a systematic review Ann Intern Med 158 2013 114 123
35. J. Amin, M.G. Law, M. Bartlett, J.M. Kaldor, and G.J. Dore Causes of death after diagnosis of hepatitis B or hepatitis C infection: a large community-based linkage study Lancet 368 2006 938 945
36. A.S. Duberg, A. Torner, L. Davidsdottir, S. Aleman, A. Blaxhult, and A. Svensson et al. Cause of death in individuals with chronic HBV and/or HCV infection, a nationwide community-based register study J Viral Hepat 15 2008 538 550
37. S.S. El-Kamary, R. Jhaveri, and M.D. Shardell All-cause, liver-related, and non-liver-related mortality among HCV-infected individuals in the general US population Clin Infect Dis 53 2011 150 157
38. S.A. McDonald, S.J. Hutchinson, S.M. Bird, P.R. Mills, J. Dillon, and M. Bloor et al. A population-based record linkage study of mortality in hepatitis C-diagnosed persons with or without HIV coinfection in Scotland Stat Methods Med Res 18 2009 271 283
39. L. Prasad, V.M. Spicher, F. Negro, M. Rickenbach, and M. Zwahlen Little evidence that hepatitis C virus leads to a higher risk of mortality in the absence of cirrhosis and excess alcohol intake: the Swiss Hepatitis C Cohort Study J Viral Hepat 16 2009 644 649
40. M.A. Crowther Introduction to surrogates and evidence-based mini-reviews Hematol Am Soc Hematol Educ Program 2009 15 16
41. M.G. Ghany, D.B. Strader, D.L. Thomas, and L.B. Seeff Diagnosis, management, and treatment of hepatitis C: an update Hepatology 49 2009 1335 1374
42. G.Y. Minuk, A. Gutkin, S.G. Wong, and K.D. Kaita Patient concerns regarding chronic hepatitis C infections J Viral Hepat 12 2005 51 57
43. P.C. Hsu, M. Krajden, E.M. Yoshida, F.H. Anderson, G.A. Tomlinson, and M.D. Krahn Does cirrhosis affect quality of life in hepatitis C virus-infected patients? Liver Int 29 2009 449 458
44. C.A. Chong, A. Gulamhussein, E.J. Heathcote, L. Lilly, M. Sherman, and G. Naglie et al. Health-state utilities and quality of life in hepatitis C patients Am J Gastroenterol 98 2003 630 638
45. A. Laupacis, D.L. Sackett, and R.S. Robert An assessment of clinically useful measurements of the consequences of treatment N Engl J Med 318 1988 1728 1733
46. G. Chatellier, E. Zapletal, D. Lemaitre, J. Menard, and P. Degoulet The number needed to treat: a clinically useful nomogram in its proper context BMJ 312 1996 426 429
47. H.H. Thein, Q. Yi, G.J. Dore, and M.D. Krahn Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression Hepatology 48 2008 418 431
48. A.J. Freeman, G.J. Dore, M.G. Law, M. Thorpe, J. Von Overbeck, and A.R. Lloyd et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection Hepatology 34 2001 809 816
49. G.J. Dore, A.J. Freeman, M. Law, and J.M. Kaldor Is severe liver disease a common outcome for people with chronic hepatitis C? J Gastroenterol Hepatol 17 2002 423 430
50. B.D. Smith, R.L. Morgan, G.A. Beckett, Y. Falck-Ytter, D. Holtzman, and J.W. Ward Hepatitis C virus testing of persons born during 1945-1965: recommendations from the centers for disease control and prevention Ann Intern Med 157 2012 817 822
51. N. Martin, P. Vickerman, J. Grebly, M. Hellard, S. Hutchinson, and V.D. Lima et al. Hepatits C virus treatment for prevention among persons who inject drugs: modelling treatment scale-up in the age of direct-acting antivirals Hepatology 58 2013 1598 1609
52. B. Mathers, L. Degenhardt, C. Bucello, J. Lemon, L. Wiessing, and M. Hickman Mortality among people who inject drugs: a systematic review and meta-analysis Bull World Health Organ 91 2013 102 123
53. Allen E, Taylor A, Palmateer N, Hutchinson S, Rees C, Johnston L, et al. The Needle Exchange Surveillance Initiative (NESI): Prevalence of HCV and injecting risk behaviours among injecting drug users attending needle exchanges in Scotland, 2008/2009. Available online at http://www.hepatitisscotlandc.org. uk/media/50084/nesi-report-08-09.pdf.
54. H. Yoshida, R. Tateishi, Y. Arakawa, M. Sata, S. Fujiyama, and S. Nishiguchi et al. Benefit of interferon therapy in hepatocellular carcinoma prevention for individual patients with chronic hepatitis C Gut 53 2004 425 430
55. L.J. McGarry, V.S. Pawar, H.R. Panchmatia, J.L. Rubin, G.L. Davis, and Z.M. Younossi et al. Economic model of a birth cohort screening program for hepatitis C virus Hepatology 55 2012 1344 1355
56. W.R. Kim, J.J. Poterucha, J.T. Benson, and T.M. Therneau The impact of competing risks on the observed rate of chronic hepatitis C progression Gastroenterology 127 2004 749 755
57. H.A. Innes, S.J. Hutchinson, S. Barclay, E. Cadzow, J.F. Dillon, and A. Fraser et al. Quantifying the fraction of cirrhosis attributable to alcohol among chronic hepatitis C virus patients: Implications for treatment cost-effectiveness Hepatology 57 2013 451 460
58. D. Schuppan, and N.H. Afdhal Liver cirrhosis Lancet 371 2008 838 851
59. H.B. El-Serag, H. Hampel, C. Yeh, and L. Rabeneck Extrahepatic manifestations of hepatitis C among United States male veterans Hepatology 36 2002 1439 1445
60. T.P. Giordano, L. Henderson, O. Landgren, E.Y. Chiao, J.R. Kramer, and H. El-Serag et al. Risk of non-hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus JAMA 297 2007 2010 2017
61. H. Uto, S.O. Stuver, K. Hayashi, K. Kumagai, F. Sasaki, and S. Kanmura et al. Increased rate of death related to presence of viremia among hepatitis C virus antibody-positive subjects in a community-based cohort study Hepatology 50 2009 393 399
62. H.E. Harris, M.E. Ramsay, and N.J. Andrews Survival of a national cohort of hepatitis C virus infected patients, 16 years after exposure Epidemiol Infect 134 2006 472 477
63. L.B. Seeff, Z. Buskell-Bales, E.C. Wright, S.J. Durako, H.J. Alter, and F.L. Iber et al. Long-term mortality after transfusion-associated non-A, non-B hepatitis. The National Heart, Lung, and Blood Institute Study Group N Engl J Med 327 1992 1906 1911
64. K.B. Kielland, K. Skaug, E.J. Amundsen, and O. Dalgard All-cause and liver-related mortality in hepatitis C infected drug users followed for 33 years: a controlled study J Hepatol 58 2013 31 37
65. S. Petta, D. Torres, G. Fazio, C. Camma, D. Cabibi, and V. Di Marco et al. Carotid atherosclerosis and chronic hepatitis C: a prospective study of risk associations Hepatology 55 2012 1317 1323
66. Life Tables for Great Britain, 2008-2010. http://www.ons.gov.uk/ons/ taxonomy/index.html?nscl=Interim+Life+Tables. Accessed January 2013.